Tag: Eli Lilly and Co

Healthy Returns: First Ozempic generics in Canada will be a test case for Novo Nordisk

Novo Nordisk CEO says the drugmaker is more active than ever in seeking out deals

Novo Nordisk’s Wegovy head start on pills forces investors to rethink Eli Lilly’s GLP-1 dominance

Weight loss and hair loss: The growing hair treatment market from GLP-1s

Eli Lilly shares surge on a beat-and-raise, proving the stock’s swoon was a mistake

Dow is surging, Nasdaq is lagging. The two factors splitting the markets in half: Live updates

FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies

Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket

More than 20,000 people are taking Eli Lilly’s weight loss pill Foundayo, CEO says

Pharma bets a little-known form of cholesterol will underpin its next blockbuster heart drugs